Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Consensus Rating of “Hold” by Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have received a consensus rating of “Hold” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $4.79.

MRNS has been the topic of a number of recent research reports. TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. StockNews.com started coverage on Marinus Pharmaceuticals in a report on Monday, November 18th. They set a “hold” rating for the company. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. Finally, Truist Financial cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th.

Marinus Pharmaceuticals Price Performance

Marinus Pharmaceuticals stock opened at $0.33 on Tuesday. The company’s 50-day moving average price is $1.11 and its two-hundred day moving average price is $1.27. The stock has a market cap of $17.94 million, a P/E ratio of -0.13 and a beta of 1.26. Marinus Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $11.26.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 DIFC Ltd bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth $28,000. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals during the second quarter worth about $34,000. AQR Capital Management LLC raised its stake in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Marinus Pharmaceuticals in the second quarter worth about $64,000. Finally, Values First Advisors Inc. boosted its stake in shares of Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 52,257 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.